◼ Archived
Business
🔮 holds ✗
GSK catches phase 3 fever after mRNA flu vaccine beats standard shots
GSK's mRNA flu vaccine is advancing to Phase 3 trials after outperforming standard shots in Phase 2.
Mrna
16 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Mrna
This hub groups 16 separate news trends connected to Mrna, spanning June 19, 2026 through September 1, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 139 article observations and 130 source signals, led by Business, Health coverage. Use it to compare how individual events emerged, spread and changed over time.
◼ Archived
Business
BioNTech-Genentech cancer vax records more deaths than control in scrapped ph. 2 test
BioNTech and Roche have halted a mid-stage cancer vaccine trial after more deaths occurred in the treatment group than in the control group.
◼ Archived
Health
🔮 fades ✓
With mRNA back in the spotlight, tRNA shows potential to treat genetic disease
A new RNA therapy approach offers hope for genetic diseases that current drugs miss
◼ Archived
Business
🔮 fades ✓
Moderna, Merck breakthrough could usher in wave of cancer vaccines
A cancer vaccine breakthrough is stirring debate over profits and public health, as Moderna and Merck's stock prices surge.
◼ Archived
Health
🔮 fades ✓
Experimental Drug Generates Immune Response Against Pancreatic Cancer in People at High Risk
An experimental vaccine is generating immune responses against pancreatic cancer in high-risk individuals, according to early clinical findings.
◼ Archived
Business
🔮 fades ✓
Moderna Shares Double on Success of mRNA Cancer Vaccine
Moderna's shares have doubled since August 19th, 2026, as investors react to a breakthrough in cancer treatment.
◼ Archived
Business
Moderna surges as Merck-partnered melanoma vaccine cuts recurrence in large trial
Moderna's stock surges as a melanoma vaccine developed with Merck shows promise in a large trial
◼ Archived
Business
🔮 fades ✓
Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial
Moderna's stock surged 160% after the company and Merck announced success in a late-stage melanoma vaccine trial
◼ Archived
Health
A new flu vaccine geared to older people is coming soon
The FDA has officially approved the first mRNA-based influenza vaccine, specifically designed to target the health needs of older Americans.
◼ Archived
Business
🔮 holds ✗
F.D.A. Approves Moderna’s mRNA Flu Vaccine
The FDA's approval of Moderna's mRNA flu vaccine marks a significant shift in seasonal flu prevention, particularly for older adults.
◼ Archived
Health
🔮 fades ✓
FDA approves 1st mRNA flu shot, from Moderna
The FDA has approved the first mRNA flu vaccine, marking a significant shift in flu shot technology.
◼ Archived
Health
🔮 fades ✓
Moderna begins Phase 1 clinical trial of Ebola vaccine against strain behind DRC outbreak
Moderna's Phase 1 Ebola vaccine trial begins as the outbreak in DR Congo continues to spread
◼ Archived
Health
🔮 fades ✗
Targeting Allele-Specific Faulty MRNA In SCNA2 Mutation Patients
8 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Health
🔮 fades ✓
An HIV vaccine is within reach thanks to mRNA
Recent breakthroughs in mRNA technology have brought an HIV vaccine closer to reality.
◼ Archived
Health
🔮 fades ✗
Only 13% survive this cancer. A blood test just detected 90% of early cases
A new blood gene test has demonstrated the ability to detect 90% of early-stage pancreatic cancers, a disease with a 13% survival rate.
◼ Archived
Business
🔮 fades ✓
New First-of-Its-Kind Flu Vaccine Approved by FDA Expert Panel
An FDA advisory panel has unanimously endorsed Moderna's first-of-its-kind mRNA-based seasonal influenza vaccine, mRNA-1010.